Video 0:30
Video
Bayer Plans $2.2 Billion Biopharmaceutical Facility in New Albany
Read the full articleThe phased biomanufacturing campus is expected to create 600 permanent jobs, supported by state training and economic incentives.
How we know this
The sources and records behind this story, with the facts they support.
Supporting evidence (14)
Global life sciences corporation Bayer announced plans on Friday, Oct. 2, 2026, to invest $2.2 billion in a new biopharmaceutical manufacturing campus in the New Albany International Business Park globenewswire-announce.
Read supporting passage
Ohio Governor Mike DeWine joined Bayer and JobsOhio today to announce Bayer’s plans to invest $2.2 billion in a new pharmaceutical manufacturing site in New Albany, Ohio.
The project is expected to create approximately 600 high-value permanent positions and generate roughly 1,500 construction jobs during development globenewswire-jobs.
Read supporting passage
Bayer is expected to create around 600 high-value jobs in the New Albany International Business Park and roughly 1,500 construction jobs during the facility’s construction.
Mike DeWine said in a statement released on Friday globenewswire-dewine.
Read supporting passage
“Bayer is a globally respected life sciences company that could have chosen to build this new facility anywhere in the United States — and it chose Ohio,” said Governor Mike DeWine. “This project firmly solidifies Ohio’s place among global biomanufacturing leaders as a destination for life sciences investment.”
The planned New Albany development will feature a flexible, modular design combining active drug substance production and finished drug product manufacturing globenewswire-portfolio.
Read supporting passage
The flexible, modular campus will be designed to combine drug substance and drug product manufacturing, leverage advanced digital and automation technologies, and support Bayer’s growing portfolio in oncology, cardiovascular and renal care.
The facility is designed to support Bayer's pharmaceutical therapies in oncology, cardiovascular conditions, and renal care globenewswire-portfolio.
Read supporting passage
The flexible, modular campus will be designed to combine drug substance and drug product manufacturing, leverage advanced digital and automation technologies, and support Bayer’s growing portfolio in oncology, cardiovascular and renal care.
The first module, focused on drug substance manufacturing, is scheduled to become operational in 2031 globenewswire-schedule.
Read supporting passage
The first module, dedicated to drug substance manufacturing, is expected to become operational in 2031. A second module for drug product manufacturing is planned to follow in 2034.
A second module dedicated to drug product manufacturing is scheduled to follow in 2034 globenewswire-schedule.
Read supporting passage
The first module, dedicated to drug substance manufacturing, is expected to become operational in 2031. A second module for drug product manufacturing is planned to follow in 2034.
This landmark investment underscores our commitment," Bayer CEO Bill Anderson said globenewswire-anderson.
Read supporting passage
“Bayer has long seen the United States as a key manufacturing base and innovation hub. This landmark investment underscores our commitment,” said Bayer CEO Bill Anderson.
Bayer plans to partner with the Ohio Life Science Training Center, an under-construction facility in New Albany scheduled to open in summer 2027 to prepare biomanufacturing technicians and equipment operators globenewswire-training.
Read supporting passage
Bayer will draw on the Ohio Life Science Training Center, under construction and scheduled to open in summer 2027, to train Ohioans to work as biomanufacturing operators and technicians. JobsOhio is investing up to $30 million in the center, alongside nearly $8 million from the City of New Albany, the State of Ohio and The New Albany Company, as part of a strategy that makes life sciences an economic development priority for the state.
JobsOhio is contributing up to $30 million toward the training facility, paired with nearly $8 million from the City of New Albany, the State of Ohio, and The New Albany Company globenewswire-training.
Read supporting passage
Bayer will draw on the Ohio Life Science Training Center, under construction and scheduled to open in summer 2027, to train Ohioans to work as biomanufacturing operators and technicians. JobsOhio is investing up to $30 million in the center, alongside nearly $8 million from the City of New Albany, the State of Ohio and The New Albany Company, as part of a strategy that makes life sciences an economic development priority for the state.
Nauseef globenewswire-nauseef.
Read supporting passage
“Bayer didn't just choose a site. It chose a workforce,” said JobsOhio President and CEO J.P. Nauseef.
Bayer plans to seek a Job Creation Tax Credit through the Ohio Department of Development at an upcoming Ohio Tax Credit Authority meeting globenewswire-incentives.
Read supporting passage
The Bayer project will pursue a Job Creation Tax Credit from the Ohio Department of Development at a future Tax Credit Authority meeting. The company also plans to pursue JobsOhio assistance for the project, which would be made public after a final agreement is executed.
The company also intends to request financial assistance from JobsOhio, which the economic development agency will disclose after executing a final agreement globenewswire-incentives.
Read supporting passage
The Bayer project will pursue a Job Creation Tax Credit from the Ohio Department of Development at a future Tax Credit Authority meeting. The company also plans to pursue JobsOhio assistance for the project, which would be made public after a final agreement is executed.
Bayer's arrival deepens the life sciences presence within the New Albany International Business Park, where it joins existing operations and facilities operated by Amgen, American Regent, and Pharmavite, as well as telehealth provider Hims & Hers globenewswire-cluster.
Read supporting passage
Bayer joins a growing life sciences cluster in the New Albany International Business Park that includes Amgen, Hims & Hers, American Regent and Pharmavite.
Supporting evidence (2)
Sebastian Guth, global chief operating officer of Bayer Pharmaceuticals and president of Bayer U.S., said the expansion represents a critical move for the company's largest market businesswire-guth.
Read supporting passage
“The United States is a key market for Bayer’s Pharmaceuticals division. This expansion is another important step to grow our pharmaceuticals business and to meet the demand of our customers and patients in the U.S., our fastest-growing pharmaceuticals market, and beyond,” said Sebastian Guth, Global Chief Operating Officer, Bayer Pharmaceuticals and President, Bayer U.S.
This expansion is another important step to grow our pharmaceuticals business and to meet the demand of our customers and patients in the U.S., our fastest-growing pharmaceuticals market, and beyond," Guth said businesswire-guth.
Read supporting passage
“The United States is a key market for Bayer’s Pharmaceuticals division. This expansion is another important step to grow our pharmaceuticals business and to meet the demand of our customers and patients in the U.S., our fastest-growing pharmaceuticals market, and beyond,” said Sebastian Guth, Global Chief Operating Officer, Bayer Pharmaceuticals and President, Bayer U.S.